Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial entry for abemaciclib (Verzenio) in non-small cell lung cancer and breast cancer. The study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non Small Cell Lung Cancer, Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING